Biomarker Editorial: The Many Lives of the Biomarker David S. Lester Biomarker 30 December 2007 Pages: 551 - 553
Implementation of a Biomarker into Drug Development: Example of Identifying the Right Imaging “Tool” for an Oncology Study Barry T. PetersonTimothy J. McCarthyPhilip Murphy Biomarker 30 December 2007 Pages: 555 - 560
Imaging Biomarker Applications in Oncology Drug Development Janet C. MillerHomer H. PienA. Gregory Sorensen Biomarker 30 December 2007 Pages: 561 - 572
Molecular Biomarkers Omar F. LaterzaRonald C. HendricksonJohn A. Wagner Biomarker 30 December 2007 Pages: 573 - 585
A Regulatory Perspective on Validation of Surrogate Endpoints Lawrence J. Lesko Biomarker 30 December 2007 Pages: 587 - 594
Interrater Reliability for Multiple Raters in Clinical Trials of Ordinal Scale Jungo SawaToshihiko Morikawa Biostatistics 30 December 2007 Pages: 595 - 605
Notes on Test Equality in Stratified Noncompliance Randomized Trials Kung-Jong Lui Biostatistics 30 December 2007 Pages: 607 - 618
Sex Differences in QT Interval Variability and Implication on Sample Size of Thorough QT Study Lu ZhangBrian P. Smith Biostatistics 30 December 2007 Pages: 619 - 627
Some Comments on Improving Collaboration Skills of the Statistician on a Drug Development Team James R. Johnson Biostatistics 30 December 2007 Pages: 629 - 632
Using Data Mining to Predict Safety Actions from FDA Adverse Event Reporting System Data Alan M. HochbergStephanie J. ReisingerKevin Hall Biostatistics 30 December 2007 Pages: 633 - 643
The Demographic, Practice, and Prescribing Characteristics of US Clinical Investigators Harold E. GlassDaniel P. Beaudry Drug Development 30 December 2007 Pages: 645 - 651
The December Effect in FDA Drug Approvals: Assessing the Submissions Echo Hypothesis James B. GrahamErnst R. Berndt Drug Development 30 December 2007 Pages: 653 - 659
Development of an Established Name: Analyzing Stem Based United States Adopted Naming Patrick M. CarpenterRobyn A. Bruce Regulatory Affairs 30 December 2007 Pages: 661 - 672
How to Improve Complex Drug Development? A Critical Review of FDA Advisory Meetings Pol F. Boudes Regulatory Affairs 30 December 2007 Pages: 673 - 684
A Statistician’s Viewpoint of Responders in the Treatment of Neuropathic Pain Ling Chen Continuing Education 30 December 2007 Pages: 685 - 689